BIOMAT Database Logo BIOMAT Database Logo

Immunologic status, granulocyte chemotaxis and antibodies to HTLVIII/LAV in haemophiliacs treated with clotting factor concentrates. 1987

G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari

UI MeSH Term Description Entries
D008297 Male Males
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D002464 Cell Migration Inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated LEUKOCYTES or MACROPHAGES. Specific CELL MIGRATION ASSAYS have been developed to estimate levels of migration inhibitory factors, immune reactivity against tumor-associated antigens, and immunosuppressive effects of infectious microorganisms. Chemotaxis Inhibition,Chemotaxis Inhibitions,Inhibition, Chemotaxis,Inhibitions, Chemotaxis
D002633 Chemotaxis The movement of cells or organisms toward or away from a substance in response to its concentration gradient. Haptotaxis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates.
June 1988, Journal of medical virology,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
T-lymphocyte subpopulations in Spanish haemophiliacs treated with commercial clotting factor concentrates.
January 1983, Antibiotics and chemotherapy,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Acute hepatitis C in haemophiliacs due to "virus-inactivated" clotting factor concentrates.
December 1992, Thrombosis and haemostasis,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Absence of antibodies to LAV/HTLV-III in haemophiliacs treated with heat-treated factor VIII concentrate of American origin.
October 1985, Lancet (London, England),
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Hepatitis, type B in haemophiliacs. Relation to the source of clotting factor concentrates.
March 1977, Scandinavian journal of haematology,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Clinical studies with treated clotting factor concentrates.
January 1987, Developments in biological standardization,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
October 1993, Lancet (London, England),
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Pregnancy and HTLVIII/LAV transmission in heroin users.
November 1986, Health bulletin,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.
August 1983, Thrombosis and haemostasis,
G Gamba, and G Ippoliti, and G Bajani, and G Ricevuti, and A Mazzone, and G Badarida, and P Gobbi, and D Geroldi, and E Ascari
Parvovirus B19 transmission by heat-treated clotting factor concentrates.
November 2002, Transfusion,
Copied contents to your clipboard!